Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference
Kiora 製藥將出席 Citizens JMP 生命科學會議
May 08, 2024 7:00am EDT Download as PDF
美國東部時間 2024 年 5 月 8 日上午 7:00 以 PDF 格式下載
Encinitas, California--(Newsfile Corp. - May 8, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at The Citizens JMP Life Sciences Conference on Tuesday May 14th, 2024 at 1:00 pm EDT.
加利福尼亞州恩西尼塔斯--（Newsfile Corp.，2024年5月8日）——Kiora Pharmicals（納斯達克股票代碼：KPRX）邀請投資者在5月14日星期二的Citizens JMP生命科學會議上觀看公司的在線演講第四，2024 年美國東部時間下午 1:00。
Kiora's presentations can be accessed live from the homepage of the investor relations section on Kiora's website (ir.kiorapharma.com) and will be available for replay for 90 days on the investor relations "events" page.
Kiora的演示可以從主頁上實時觀看 投資者關係 Kiora 網站上的欄目 (ir.kiorapharma.com），並將在投資者關係 “活動” 頁面上重播90天。
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
關於 Kiora 製藥
Kiora Pharmaceuticals是一家臨床階段的生物技術公司，正在開發和商業化治療孤兒視網膜疾病的產品。KIO-301 正在開發用於治療色素性視網膜炎、脈絡膜血癥和斯塔加特病。它是一種分子光電開關，有可能恢復遺傳性和/或年齡相關性視網膜變性患者的視力。KIO-104 正在開發用於治療後部非感染性葡萄膜炎。它是二氫乳清酸脫氫酶的下一代非甾體免疫調節小分子抑制劑。
In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
除了新聞稿和美國證券交易委員會文件外，我們還希望在我們的網站上發佈信息（www.kiorapharma.com）以及可能與投資者相關的社交媒體賬戶。我們鼓勵投資者在推特和領英上關注我們，訪問我們的網站和/或訂閱電子郵件提醒。
Contacts:
聯繫人：
Investors
investors@kiorapharma.com
Media
kiora@crowepr.com
Crowe PR
媒體
kiora@crowepr.com
Crowe PR
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/208302
要查看本新聞稿的源版本，請訪問 https://www.newsfilecorp.com/release/208302
SOURCE Kiora Pharmaceuticals, Inc.
來源 Kiora 製藥公司
Released May 8, 2024
2024 年 5 月 8 日發佈
譯文內容由第三人軟體翻譯。